Aquavit Pharmaceuticals Appoints David J. Goldberg As Chief Medical Officer

NEW YORK, March 5, 2014 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc., a private high-tech life science company, announced today the appointment of David J. Goldberg, MD., JD. as its Chief Medical Officer. Dr. Goldberg is a renowned dermatologist and is recognized nationally and internationally for his innovative work with skin lasers, cosmetic dermatology and facial rejuvenation techniques. Prior to joining Aquavit, Dr. Goldberg has served as President of ASLMS and is and or was on the Board of Directors of AAD, ASLMS and ASDS. Additionally, Dr. Goldberg is a Clinical Professor of Dermatology and Director of Laser Research at Mount Sinai School of Medicine, a Clinical Professor of Dermatology and Chief of Dermatologic Surgery at Rutgers New Jersey Medical School as well as the Chief of Dermatology at Hackensack University Medical Center and an Adjunct Professor of Law at Fordham Law School and teaches a course entitled "Advances in Health Care Law".

"We are thrilled to have Dr. Goldberg on board. He is an exceptional physician, researcher, and most importantly, a visionary with passion in life," said Sobin Chang, CEO of Aquavit Pharmaceuticals. "He is an entrepreneur, a perfect addition to the Aquavit team as we continue to enhance our growing product portfolio."

Dr. Goldberg earned his medical degree from Yale University School of Medicine and completed his dermatology residency and dermatologic surgical fellowship at New York University Medical Center and his law degree from Fordham School of Law. He is a Board certified Dermatologist, having published over 150 peer-reviewed manuscripts and is author of books on Laser Hair Removal; Cellulite and Fat Removal, Acne and Rosacea, Ablative and Non-ablative Skin Rejuvenation; Photodamaged Skin, Complications in Cutaneous Laser Surgery, Laser Dermatology, and Dermal Fillers. Dr. Goldberg is today Editor in Chief of the Journal of Cosmetic and Laser therapy and serves as an editorial board member of both Lasers in Surgery and Medicine and Dermatologic Surgery. Dr. Goldberg's arrival will provide valuable expertise in advancing Aquavit's strategic research and development commitment to addressing the challenge of unmet need in personalized medicine.

About Aquavit Pharmaceuticals, Inc.

Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. For more information, visit

About David Goldberg, M.D.

David J. Goldberg, M.D. is recognized nationally and internationally for his innovative work with skin lasers, cosmetic dermatology and facial rejuvenation techniques. A board-certified dermatologist who has been in practice since 1985, he has treated patients and taught doctors throughout the world in the use of these cutting-edge technologies. Dr. Goldberg is active in professional societies and was elected president of the American Society for Lasers in Medicine & Surgery. Dr. Goldberg was recently elected to the board of directors of the American Academy of Dermatology and Secretary to the board of directors of the American Society for Dermatologic Surgery. He also serves as a co-vice-president of the Skin Cancer Foundation. Dr. Goldberg was the first recipient of the prestigious Leon Goldman award, named after the founder of laser surgery.

SOURCE Aquavit Pharmaceuticals, Inc.

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.